Johnson & Johnson said the FDA approved Icotyde (icotrokinra), a once-daily oral treatment for adults with moderate to severe ...

Johnson & Johnson and Protagonist Therapeutics are countering the swarm of injectable biologics that have long dominated the ...

Protagonist Therapeutics (NASDAQ:PTGX) executives said March 18 that the U.S. Food and Drug Administration has approved ...

Icotyde is the first targeted oral peptide IL‑23 receptor antagonist, designed to interrupt a core psoriasis inflammatory axis while avoiding injection-based administration typical of IL‑23 biologics.

FDA authorization covers moderate-to-severe plaque psoriasis in adults and patients aged ≥12 years, expanding systemic options for adolescents. Icotrokinra is characterized as a first-in-class ...

Johnson & Johnson won U.S. approval for a daily psoriasis pill that rivals the benefits of injectable medicines and could roil a multibillion-dollar market.

Johnson & Johnson (JNJ) stock is in focus as US approves its once-daily pill Icotyde developed with Protagonist Therapeutics (PTGX) for plaque psoriasis. Read more here.

Oral icotrokinra is now FDA-approved for plaque psoriasis, offering a new systemic option for adults and adolescents who weigh at least 40kg.

The FDA approved icotrokinra for adults and adolescents aged 12 years and older with moderate to severe plaque psoriasis, Johnson & Johnson announced in a press release. Icotrokinra (Icotyde) is the ...

Protagonist Therapeutics recently received U.S. FDA approval for ICOTYDE (icotrokinra) to treat adults with moderate to severe plaque psoriasis, and held a special call on March 18, 2026 to discuss ...

This is the first IL-23 receptor-targeted oral peptide pill, and it is also being evaluated as a treatment for psoriatic ...